RecruitingPhase 3NCT01649830
Efficacy of Post-radiation Adjuvant Temozolomide Chemotherapy in Residue Low-grade Glioma
Studying Low-grade astrocytoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sun Yat-sen University
- Principal Investigator
- Zhong-ping CHEN, MD, PhDSun Yat-sen University
- Intervention
- Radiotherapy(radiation)
- Enrollment
- 290 enrolled
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2012 – 2026
Study locations (1)
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01649830 on ClinicalTrials.govOther trials for Low-grade astrocytoma
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT04576117A Study to Compare Treatment With the Drug Selumetinib Alone Versus Selumetinib and Vinblastine in Patients With Recurrent or Progressive Low-Grade GliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE3NCT04166409A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade GliomaNational Cancer Institute (NCI)